Differing approaches could decide oncology race
Bristol-Myers Squibb looked like the frontrunner in the lung cancer race for a long time, but a different – and perhaps outdated – approach means it has lost ground to rivals Roche and Merck.
BY STEFAN SINGH KAILAY
The immuno-oncology battle has been heating up lately, and that has been a great talking point across the Atlantic toward the end of the summer, says Claus Henrik Johansen, senior portfolio manager in the Wealth Management department of Danske Bank.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Bavarian Nordic strikes new deal with BMS
For abonnenter
